Perkins Capital Management Inc. Sells 415 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Perkins Capital Management Inc. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,786 shares of the medical instruments supplier’s stock after selling 415 shares during the period. LeMaitre Vascular makes up approximately 2.9% of Perkins Capital Management Inc.’s investment portfolio, making the stock its 9th biggest position. Perkins Capital Management Inc.’s holdings in LeMaitre Vascular were worth $3,138,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth $283,000. Harbor Capital Advisors Inc. grew its position in LeMaitre Vascular by 113.3% in the third quarter. Harbor Capital Advisors Inc. now owns 24,093 shares of the medical instruments supplier’s stock valued at $2,238,000 after acquiring an additional 12,797 shares during the last quarter. F M Investments LLC raised its stake in LeMaitre Vascular by 36.6% during the third quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier’s stock worth $11,476,000 after acquiring an additional 33,087 shares in the last quarter. James Investment Research Inc. bought a new position in shares of LeMaitre Vascular in the third quarter worth about $201,000. Finally, Conestoga Capital Advisors LLC boosted its stake in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after purchasing an additional 36,850 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 3.1 %

NASDAQ LMAT opened at $101.71 on Thursday. The firm has a market capitalization of $2.29 billion, a PE ratio of 55.58, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89. The business’s 50-day moving average price is $90.13 and its two-hundred day moving average price is $83.87. LeMaitre Vascular, Inc. has a 12 month low of $47.72 and a 12 month high of $103.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. The firm’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 earnings per share. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.63%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.97%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Lake Street Capital began coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.